Wildagliptin + Metformin Hydrochloride
The active substances of Ipinzan are wildagliptin and metformin, which belong to a group of oral antidiabetic medicines.
Ipinzan is used to treat adult patients with type 2 diabetes. This type of diabetes is also called non-insulin-dependent diabetes. Ipinzan is used when diet and exercise alone are not enough to control your blood sugar levels and when your doctor decides to add Ipinzan to your treatment (with or without other antidiabetic medicines such as insulin or sulfonylureas).
Type 2 diabetes is a condition where the body does not produce enough insulin or where the insulin produced by the body does not work properly. Type 2 diabetes can also occur when the body produces too much glucagon.
Both insulin and glucagon are produced in the pancreas. Insulin helps to lower the level of sugar in the blood, especially after meals. Glucagon is a substance that stimulates the production of sugar in the liver and increases the level of sugar in the blood.
Both active substances, wildagliptin and metformin, help to control the level of sugar in the blood.
Wildagliptin works by stimulating the pancreas to produce more insulin and by reducing the production of glucagon. Metformin helps the body to make better use of insulin.
It has been shown that the medicine lowers the level of sugar in the blood, which may help to prevent complications of diabetes.
If you have uncontrolled diabetes, for example, severe hyperglycemia (high blood sugar levels), nausea, vomiting, diarrhea, sudden weight loss, lactic acidosis (see also "Risk of lactic acidosis" below) or diabetic ketoacidosis. Diabetic ketoacidosis is a condition where substances called ketone bodies build up in the blood and can lead to diabetic coma. Symptoms include abdominal pain, rapid and deep breathing, drowsiness, or a fruity odor from the mouth.
Before taking Ipinzan, talk to your doctor or pharmacist or nurse.
Risk of lactic acidosis
Ipinzan may cause a very rare but very serious side effect called lactic acidosis, especially if you have kidney problems. The risk of lactic acidosis increases if you have uncontrolled diabetes, severe infection, prolonged fasting or alcohol intake, dehydration (see below), liver problems, or any condition that interferes with oxygen delivery to tissues (e.g., severe heart failure).
If any of these conditions apply to you, tell your doctor.
(significant loss of body fluids), such as severe vomiting, diarrhea, fever, high temperature, or if you drink less fluid than you normally would. Talk to your doctor for advice.
as it can lead to coma. Symptoms of lactic acidosis include:
Lactic acidosis is a medical emergency that requires immediate hospital treatment.
Talk to your doctor immediately if you experience any of the following:
Before taking Ipinzan, tell your doctor or pharmacist or nurse if you are taking a sulfonylurea, a type of antidiabetic medicine. Your doctor may want to reduce the dose of the sulfonylurea you are taking with Ipinzan to avoid low blood sugar levels (hypoglycemia).
If you have taken wildagliptin before but had to stop due to liver disease, you should not take this medicine.
Diabetic skin changes are a common complication of diabetes. Follow your doctor's or nurse's advice on skin and foot care. You should also pay particular attention to the appearance of new blisters or ulcers while taking Ipinzan.
If you notice any, talk to your doctor promptly.
If you are going to have a major surgical operation, you should not take Ipinzan during or for some time after the operation. Your doctor will decide when you should stop and restart Ipinzan.
Before and during treatment with Ipinzan, and at least every 3 months during the first year of treatment, and periodically thereafter, you will have to have liver function tests to check for signs of liver damage as soon as possible.
During treatment with Ipinzan, your doctor will regularly check your kidney function at least once a year or more often if you are elderly and/or have worsening kidney function.
Your doctor will regularly check your blood sugar levels and urine.
Ipinzan should not be used in children and adolescents under 18 years of age.
If you are going to have a contrast agent injected into your bloodstream (for example, for an X-ray or CT scan), you should stop taking Ipinzan before or at the latest at the time of the injection. Your doctor will decide when you should stop and restart Ipinzan.
Tell your doctor about all the medicines you are taking or have recently taken, and about any medicines you plan to take. You may need more frequent blood sugar tests or kidney function tests, or your doctor may need to adjust your dose of Ipinzan. It is especially important to tell your doctor if you are taking:
Avoid excessive alcohol intake while taking Ipinzan, as this may increase the risk of lactic acidosis (see also "Warnings and precautions" above).
If you experience dizziness while taking Ipinzan, do not drive or operate machinery.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Always take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
The dose of Ipinzan is different for each patient. Your doctor will tell you which dose to take.
The recommended dose is one tablet of 50 mg + 850 mg or 50 mg + 1000 mg twice a day.
If you have kidney problems, your doctor may prescribe a lower dose. If you are taking a sulfonylurea, a type of antidiabetic medicine, your doctor may also prescribe a lower dose.
Your doctor may prescribe this medicine alone (as monotherapy) or with other medicines that lower blood sugar levels.
If you accidentally take too many Ipinzan tablets or if someone else takes your tablets, contact your doctor or pharmacist immediately. You may need medical attention. If you need to go to a doctor or hospital, take the pack and this leaflet with you.
If you forget to take a tablet, take it with your next meal unless it is time for your next dose. Do not take a double dose (two tablets at once) to make up for a forgotten tablet.
To keep your blood sugar levels under control, you should keep taking this medicine for as long as your doctor prescribes it. Do not stop taking Ipinzan without talking to your doctor first. If you have any questions about how long to take Ipinzan, talk to your doctor.
If you have any further questions on the use of this product, ask your doctor, pharmacist, or nurse.
Like all medicines, Ipinzan can cause side effects, although not everybody gets them.
Stop taking Ipinzan and contact your doctor immediatelyif you experience any of the following serious side effects:
Hepatic impairment (uncommon: may affect up to 1 in 100 people): Symptoms include yellowing of the skin and the whites of the eyes, nausea, loss of appetite, or dark-colored urine. These may be signs of liver damage (hepatitis).
Some patients have experienced the following side effects while taking Ipinzan:
After this medicine has been marketed, the following side effects have also been reported:
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet.
You can also report side effects directly via the national reporting system listed in the "Contact details for reporting side effects" section below.
By reporting side effects, you can help provide more information on the safety of this medicine.
Ipinzan 50 mg + 850 mg film-coated tablets are yellow, oval, biconvex tablets with a break line on one side and "50" and "850" engraved on the other side, 21.6 ± 0.2 mm in length and 8.6 ± 0.2 mm in width.
Ipinzan 50 mg + 1000 mg film-coated tablets are dark yellow, oval, biconvex tablets with a break line on one side and "50" and "1000" engraved on the other side, 22.0 ± 0.2 mm in length and 9.0 ± 0.2 mm in width.
Ipinzan is packaged in a cardboard box containing the appropriate number of blisters made of OPA/Aluminum/PVC/Aluminum or transparent PVC/PCTFE/Aluminum foil.
Ipinzan is available in packs of 10, 30, 60, or 180 film-coated tablets. Not all pack sizes may be marketed.
Zentiva k.s.
U kabelovny 130
Dolní Měcholupy
102 37 Prague 10
Czech Republic
PHARMATHEN INTERNATIONAL S.A.
Industrial Park Sapes, Rodopi Prefecture, Block No 5,
69300 Rodopi
Greece
PHARMATHEN S.A.
Dervenakion 6
15351 Pallini Attiki
Greece
For further information on this medicine, contact the local representative of the marketing authorization holder:
Zentiva Polska Sp. z o.o.
Bonifraterska 17
00-203 Warsaw
Phone: +48 22 375 92 00
Date of last revision of the package leaflet: March 2025
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.